Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2014. The document serves as a correction to a previous announcement regarding director transactions, specifically addressing an administrative error by the company's external share plan administrator concerning the number of shares sold.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a notification of transactions involving a director and does not contain consolidated financial statements.
Material Changes
The material change disclosed is a revision to the transaction details for Sir Andrew Witty, a Director, originally reported on October 23, 2014. The corrected details reflect the actual number of shares sold following the exercise of share options.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The unusual item noted is the administrative error in the share plan administration that necessitated this replacement announcement.
Important Facts for Investors
- Director Transaction Correction: Sir Andrew Witty exercised options over 77,500 Ordinary Shares on October 23, 2014, at a price of £11.23 per share.
- Share Sale Details: Following the exercise, 69,905 Ordinary Shares were sold on October 23, 2014, at a price of £13.84 per share.
- Reason for Filing: This Form 6-K replaces the original October 23 announcement due to an administrative error regarding the share count.
- Notification Date: The company was advised of the revised transaction details on November 13, 2014.